STOCK TITAN
  1. Home
  2. Sec-filings
  3. BDTX
  4. [EFFECT] Black Diamond Therapeutics, Inc. SEC Filing

[EFFECT] Black Diamond Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 3, 2025 4:01 P.M.
Form: S-3
CIK: 0001701541
Company Name: Black Diamond Therapeutics, Inc.
File Number: 333-291518

Source: View Original Filing on SEC EDGAR

Stock BDTX logo
Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

BDTX Rankings

#4681 Ranked by Market Cap
N/A Ranked by Dividends

BDTX Latest News

Dec 3, 2025
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Dec 2, 2025
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Nov 6, 2025
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Nov 6, 2025
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Aug 7, 2025
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

BDTX Latest SEC Filings

Dec 15, 2025
[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity
Dec 15, 2025
[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity
Nov 13, 2025
[S-3] Black Diamond Therapeutics, Inc. Shelf Registration Statement
Nov 6, 2025
[10-Q] Black Diamond Therapeutics, Inc. Quarterly Earnings Report
Nov 6, 2025
[8-K] Black Diamond Therapeutics, Inc. Reports Material Event

BDTX Stock Data

141.87M
56.41M
0.63%
78.82%
12.34%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE